Video

Dr. von Mehren on Outcomes With Ribociclib/Everolimus in Dedifferentiated Liposarcoma

Margaret von Mehren, MD, discusses outcomes with ribociclib and everolimus in dedifferentiated liposarcoma, as seen in the phase 2 SAR-096 trial.

Margaret von Mehren, MD, chief of the Division of Sarcoma Medical Oncology, physician director of the Clinical Trials Office, associate director of Clinical Research, and professor of the Department of Hematology/Oncology at Fox Chase Cancer Center, discusses outcomes with ribociclib (Kisqali) and everolimus (Afinitor) in dedifferentiated liposarcoma, as seen in the phase 2 SAR-096 trial (NCT03114527).

In this patient population, interesting activity was observed in terms of disease stabilization, von Mehren says. Two patients of the 21 best responders experienced a complete response or partial response, which has not been observed in previous studies examining CDK inhibitors in this patient population, she explains.

When a small study at 2 institutions is being conducted, it is difficult to call the results significant, although the finding is notably interesting and raises the question as to how future research efforts should proceed, von Mehren says. Additionally, while the combination of ribociclib and everolimus was not excessively toxic, certain patients developed neutropenia and lymphocytopenia, which limited their ability to take the regimen on a consistent basis. The dosing schema and how it was done is feasible in the long term for this patient population, von Mehren concludes.

Related Videos
2 expert is featured in this series.
2 expert is featured in this series.
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Kathleen N. Moore, MD, MS
Dana M. Chase, MD
Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center
Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine